Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Use of Sacubitril/Valsartan for Hospitalized Heart Failure—Why Do We Care About Cost and Value?

The Use of Sacubitril/Valsartan for Hospitalized Heart Failure—Why Do We Care About Cost and Value? Research Original Investigation Cost-effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction (10):e56-e528. doi:10.1161/CIR. 24. Neumann PJ, Cohen JT, Weinstein MC. 27. Anderson JL, Heidenreich PA, Barnett PG, et al; 0000000000000659 Updating cost-effectiveness—the curious resilience ACC/AHA Task Force on Performance Measures; of the $50,000-per-QALY threshold. N Engl J Med. ACC/AHA Task Force on Practice Guidelines. 22. United States Census Bureau. Current 2014;371(9):796-797. doi:10.1056/NEJMp1405158 ACC/AHA statement on cost/value methodology population survey tables for personal income. in clinical practice guidelines and performance Accessed in March 2018. https://www.census.gov/ 25. Briggs AH. Handling uncertainty in measures: a report of the American College of data/tables/time-series/demo/income-poverty/ cost-effectiveness models. Pharmacoeconomics. Cardiology/American Heart Association Task Force cps-pinc.html 2000;17(5):479-500. doi:10.2165/00019053- on Performance Measures and Task Force on 200017050-00006 23. Hunink MGM, Weinstein MC, Wittenberg E, Practice Guidelines. Circulation. 2014;129(22):2329- et al. Decision Making in Health and Medicine: 26. Roger VL. Epidemiology of heart failure. Circ Res. 2345. doi:10.1161/CIR.0000000000000042 Integrating Evidence and Values. 2nd ed. Cambridge 2013;113(6):646-659. doi:10.1161/CIRCRESAHA.113. University Press; 2014. doi:10.1017/ 300268 CBO9781139506779 Editor's Note The Use of Sacubitril/Valsartan for Hospitalized Heart Failure— Why Do We Care About Cost and Value? Clyde W. Yancy, MD, MSc; Adrian F. Hernandez, MD, MHS; Robert O. Bonow, MD, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Cardiology American Medical Association

The Use of Sacubitril/Valsartan for Hospitalized Heart Failure—Why Do We Care About Cost and Value?

The Use of Sacubitril/Valsartan for Hospitalized Heart Failure—Why Do We Care About Cost and Value?

Abstract

Research Original Investigation Cost-effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction (10):e56-e528. doi:10.1161/CIR. 24. Neumann PJ, Cohen JT, Weinstein MC. 27. Anderson JL, Heidenreich PA, Barnett PG, et al; 0000000000000659 Updating cost-effectiveness—the curious resilience ACC/AHA Task Force on Performance Measures; of the $50,000-per-QALY threshold. N Engl J Med. ACC/AHA Task Force on Practice Guidelines. 22. United States Census...
Loading next page...
 
/lp/american-medical-association/the-use-of-sacubitril-valsartan-for-hospitalized-heart-failure-why-do-gNxAr4UmIC
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2380-6583
eISSN
2380-6591
DOI
10.1001/jamacardio.2020.3108
Publisher site
See Article on Publisher Site

Abstract

Research Original Investigation Cost-effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction (10):e56-e528. doi:10.1161/CIR. 24. Neumann PJ, Cohen JT, Weinstein MC. 27. Anderson JL, Heidenreich PA, Barnett PG, et al; 0000000000000659 Updating cost-effectiveness—the curious resilience ACC/AHA Task Force on Performance Measures; of the $50,000-per-QALY threshold. N Engl J Med. ACC/AHA Task Force on Practice Guidelines. 22. United States Census Bureau. Current 2014;371(9):796-797. doi:10.1056/NEJMp1405158 ACC/AHA statement on cost/value methodology population survey tables for personal income. in clinical practice guidelines and performance Accessed in March 2018. https://www.census.gov/ 25. Briggs AH. Handling uncertainty in measures: a report of the American College of data/tables/time-series/demo/income-poverty/ cost-effectiveness models. Pharmacoeconomics. Cardiology/American Heart Association Task Force cps-pinc.html 2000;17(5):479-500. doi:10.2165/00019053- on Performance Measures and Task Force on 200017050-00006 23. Hunink MGM, Weinstein MC, Wittenberg E, Practice Guidelines. Circulation. 2014;129(22):2329- et al. Decision Making in Health and Medicine: 26. Roger VL. Epidemiology of heart failure. Circ Res. 2345. doi:10.1161/CIR.0000000000000042 Integrating Evidence and Values. 2nd ed. Cambridge 2013;113(6):646-659. doi:10.1161/CIRCRESAHA.113. University Press; 2014. doi:10.1017/ 300268 CBO9781139506779 Editor's Note The Use of Sacubitril/Valsartan for Hospitalized Heart Failure— Why Do We Care About Cost and Value? Clyde W. Yancy, MD, MSc; Adrian F. Hernandez, MD, MHS; Robert O. Bonow, MD,

Journal

JAMA CardiologyAmerican Medical Association

Published: Nov 12, 2020

References